Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2015 Apr;102(4):297-9.
doi: 10.1016/j.bulcan.2015.02.010.

[Bisphosphonates as new anticancer agents?]

[Article in French]
Jacques Robert  1 , William C Reinhold
Affiliations
Comment

[Bisphosphonates as new anticancer agents?]

[Article in French]
Jacques Robert et al. Bull Cancer. 2015 Apr.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Représentation graphique des IC50 de 20 861 composés vis-à-vis des lignées de la collection NCI-60. Les IC50 sont exprimées en valeur relative dans les lignées triple négatives (TN : MDA-MB-231, HS-578T, BT-549) et les lignées exprimant le récepteur des œstrogènes (ER+ : MCF-7, T47-D). L’acide zolédronique est repéré par un point rouge, les médicaments classiques utilisés dans le cancer du sein (capécitabine, carboplatine, cyclophosphamide, docétaxel, doxorubicine, épirubicine, fluorouracile, gemcitabine, méthotrexate, mitomycine, mitoxantrone, paclitaxel, vincristine) sont repérés par des points verts, les inhibiteurs de l’activité tyrosine kinase de l’EGFR (afatinib, erlotinib, géfitinib, lapatinib), ainsi que la rapamycine, par des points orangés
Figure 2
Figure 2
Expression du gène EGFR dans les trois types de tumeurs de la collection du TCGA : triple négatives (TN), luminales (LUM) et amplifiant le gène ERBB2 (ERBB2). La différence entre les tumeurs triple négatives et l’ensemble des autres tumeurs est significative au seuil de 10−48
See this image and copyright information in PMC

Comment on

  • Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer.
    Stachnik A, Yuen T, Iqbal J, Sgobba M, Gupta Y, Lu P, Colaianni G, Ji Y, Zhu LL, Kim SM, Li J, Liu P, Izadmehr S, Sangodkar J, Scherer T, Mujtaba S, Galsky M, Gomez J, Epstein S, Buettner C, Bian Z, Zallone A, Aggarwal AK, Haider S, New MI, Sun L, Narla G, Zaidi M. Stachnik A, et al. Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):17995-8000. doi: 10.1073/pnas.1421422111. Epub 2014 Dec 1. Proc Natl Acad Sci U S A. 2014. PMID: 25453078 Free PMC article.
  • Bisphosphonates inactivate human EGFRs to exert antitumor actions.
    Yuen T, Stachnik A, Iqbal J, Sgobba M, Gupta Y, Lu P, Colaianni G, Ji Y, Zhu LL, Kim SM, Li J, Liu P, Izadmehr S, Sangodkar J, Bailey J, Latif Y, Mujtaba S, Epstein S, Davies TF, Bian Z, Zallone A, Aggarwal AK, Haider S, New MI, Sun L, Narla G, Zaidi M. Yuen T, et al. Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):17989-94. doi: 10.1073/pnas.1421410111. Epub 2014 Dec 1. Proc Natl Acad Sci U S A. 2014. PMID: 25453081 Free PMC article.

References

    1. Yuen T, Stachnik A, Iqbal J, et al. Bisphosphonates inactivate human EGFRs to exert antitumor actions. Proc Natl Acad Sci U S A 2014;111:17989–94. - PMC - PubMed
    1. Stachnik A, Yuen T, Iqbal J, et al. Repurposing of bisphosphonates for the prevention and therapy of non-small cell lung and breast cancer. Proc Natl Acad Sci U S A 2014;111:17995–8000. - PMC - PubMed
    1. Coleman R, Gnant M, Morgan G et al. Effects of bone-targeted agents on cancer progression and mortality. J Nat Cancer Inst 2012;104: 1059–67. - PubMed
    1. Rennert G, Pinchev M, Rennert HS et al. Use of bisphosphonates and reduced cancer risk of colorectal cancer. J Clin Oncol 2011;29: 1146–50. - PMC - PubMed
    1. Reinhold WC, Sunshine M, Liu H, et al. CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res 2012;72:3499–511. - PMC - PubMed

MeSH terms

LinkOut - more resources